 - Patients previously diagnosed with low-risk Gleason score 6, clinical stage T2a, and PSA 10 ngmL prostate cancer undergoing active surveillance who are re-biopsied and found to have intermediate-risk disease according to the protocol criteria are eligible for enrollment within 6 months of the repeat biopsy procedure 